{"organizations": [], "uuid": "4c5b9536ae05f6524c93e9ab15ad5a5b5fbf73a3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-roche-drugs-chief-says-erosion-in/brief-roche-drugs-chief-says-erosion-in-european-rituxan-sales-to-intensify-in-2018-as-biosimilars-enter-more-markets-after-26-percent-4th-quarter-drop-idUSFWN1PR15Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Roche Drugs Chief Says Erosion In European Rituxan Sales To Intensify In 2018 As Biosimilars Enter More Markets After 26 Percent 4th Quarter Drop", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.059, "site_type": "news", "published": "2018-02-02T00:41:00.000+02:00", "replies_count": 0, "uuid": "4c5b9536ae05f6524c93e9ab15ad5a5b5fbf73a3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-roche-drugs-chief-says-erosion-in/brief-roche-drugs-chief-says-erosion-in-european-rituxan-sales-to-intensify-in-2018-as-biosimilars-enter-more-markets-after-26-percent-4th-quarter-drop-idUSFWN1PR15Q", "ord_in_thread": 0, "title": "BRIEF-Roche Drugs Chief Says Erosion In European Rituxan Sales To Intensify In 2018 As Biosimilars Enter More Markets After 26 Percent 4th Quarter Drop", "locations": [], "entities": {"persons": [{"name": "john miller", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Roche:\n* DRUGS CHIEF SAYS EROSION IN EUROPEAN RITUXAN SALES TO INTENSIFY IN 2018 AS BIOSIMILARS ENTER MORE MARKETS AFTER 26 PERCENT 4TH QUARTER DROP Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T00:41:00.000+02:00", "crawled": "2018-02-01T19:19:02.026+02:00", "highlightTitle": ""}